Trend Results : Juno Therapeutics


Blog Post Results (1-20 of 52)

FILTER RESULTS

Celgene to buy Juno for $9 billion

Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports. Video provided by Reuters        

WALL STREET PAYDAY: 4 banks made a killing from Monday's $20 billion in biotech deals

Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics. Investment...Show More Summary

Celgene to buy Juno for $9 billion to boost cancer pipeline

(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.

The hottest thing in cancer drug development just won a $9 billion endorsement

Biotech giant Celgene is acquiring Juno Therapeutics for $9 billion. Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy, which harnesses the body's immune system to go after certain blood cancers. It's part of a new field of cancer therapies that. Show More Summary

Celgene to buy Juno for $9 billion to boost CAR-T expertise

(Reuters) - Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as it moves to cement its position as a key player in a new range of cancer therapies.

Incurable blood cancers targeted in Celgene's $9B deal to acquire Juno Therapeutics

last monthNews : USAToday: News

Biopharmaceutical firm Celgene will pay about $9 billion to acquire the shares of Juno Therapeutics that it doesn't already hold.        

Two drug companies are exploding after a pair of biotech mega-deals (BIVV, JUNO)

French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments, in a deal worth $9 billion. Both stocks are up bigShow More Summary

Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion (CELG, JUNO)

Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion. It's be the second in 2018 for the biotech giant, which has been under pressure from investors. The highly personalized...Show More Summary

The hottest thing in cancer drug development is a takeover target again — here's what you need to know about it (JUNO, CELG)

Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that use the body's...Show More Summary

Juno Therapeutics jumps 53% after report Celgene is interested in buying the cancer drugmaker

Shares of Juno Therapeutics are up more than 50% in early trading on Wednesday following a Wall Street Journal report Tuesday evening that biotech giant Celgene is in talks to buy the cancer drugmaker. Juno is developing a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor). Show More Summary

Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker

Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors. Juno is known for...Show More Summary

Novartis touts new T-cell therapy data in race for FDA approval

9 months agoHealth : Reuters: Health

ZURICH (Reuters) - Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Biotech Firm Halts 'Revolutionary' Cancer Treatment After Patient Deaths

12 months agoTechnology / Gadgets : Gizmodo

Following the deaths of five patients, Juno Therapeutics has decided to pull the plug on an experimental cancer treatment that boosts the power of a patient’s immune cells. The news comes just days after the company’s rival, Kite Pharma, announced its success with a similar method, showing there’s still hope for this… Read more...

Juno ends development of high-profile leukemia drug after deaths

12 months agoHealth : Reuters: Health

(Reuters) - Juno Therapeutics Inc on Wednesday said it decided to shut down development of an experimental leukemia treatment from a highly promising new class of immunotherapy following an investigation into toxicity that led to a handful of patient deaths.

Fred Hutch to Hold Grand Opening of Bezos Family Immunotherapy Clinic

Leaders from Fred Hutch, Seattle Cancer Care Alliance and Juno Therapeutics will speak on immunotherapy's roots in Seattle, new clinical trials and the prospects for developing new cures for cancer during a Dec. 12 scientific symposium to celebrate the opening of the first-of-its-kind clinic

Copyright © 2015 Regator, LLC